

**VIROTECH RSV IgG/IgM ELISA
(RSV IgG/IgM ELISA)**

Order No.: EC107.00

RSV IgA-Set

Order No.: EC107.08

Color Coding: light green

FOR IN VITRO DIAGNOSIS ONLY

**VIROTECH Diagnostics GmbH
Löwenplatz 5
D- 65428 Rüsselsheim**

Tel.: +49-6142-6909-0

Fax: +49-6142-966613

<http://www.virotechdiagnostics.com>



Contents

1. Intended Use.....	3
2. Diagnostic Relevance.....	3
3. Test Principle.....	3
4. Package Contents	3
4.1 IgG/IgM Testkit.....	3
4.2 IgA Set.....	4
5. Storage and Shelflife of the Testkit and the ready to use reagents	4
6. Precautions and Warnings.....	4
7. Material required but not supplied	4
8. Test Procedure	5
8.1 Examination Material.....	5
8.2 Preparation of Reagents	5
8.3 VIROTECH ELISA Test Procedure	5
8.4 Usage of ELISA processors	6
9. Test Evaluation.....	6
9.1 Test function control.....	6
9.2 Calculation of the VIROTECH Units (VE)	6
9.3 Interpretation Scheme IgG, IgM and IgA	6
9.4 Limits of the Test.....	7
10. Performance Data	7
10.1 Sensitivity and Specificity.....	7
10.2 Prevalence (Expected Values)	7
10.3 Intra-assay-Coefficient of Variation (Repeatability)	7
10.4 Inter-assay-Coefficient of Variation (Reproducibility)	7
11. Literature.....	8
12. Test Procedure Scheme	9

1. Intended Use

The RSV ELISA is intended for the qualitative and semiquantitative detection of IgG-, IgM- and IgA-antibodies against Respiratory syncytial Virus (RSV) in human serum.

2. Diagnostic Relevance

RSV is an RNA virus from the paramyxovirus family. It is a single-strand virus with shell and there are 2 known main strains, A and B. It is believed that strain A has a higher incidence and demonstrates greater virulence.

RSV follows a typical seasonal pattern between autumn and spring with annual variations and most cases occur between January and March. The incubation period of RSV is about 5 days. Infected patients shed the virus for 3 to 8 days, and neonates and immunodeficient patients for much longer. The virus is spread not only as a droplet infection, e.g. by coughing, but often as a contact infection also.

In the first two years of life, every child gets an RSV infection at least once. Thus, 50% of 1-year olds and nearly 100% of 2-year olds demonstrate RSV antibodies (other sources report an infection rate of 80% (5)). The disease can have a very varied presentation, extending from a simple cold to severe pneumonia (1). Although the prevalence is high it comes to a reinfection in up to about 75% with reexposure, but second and following infections have a milder clinical progress (2).

RSV is the commonest cause of infection of the lower respiratory tract in the first year of life and is also the commonest cause (74%) of acute viral otitis media. Particularly in the first two years of life, the disease can follow a severe course.

Reinfections after the second year of life are not infrequent, but are usually milder in healthy persons and sometimes have no symptoms. The treatment of RSV infection is largely symptomatic.

However, when immune functions are impaired, e.g. during chemotherapy, RSV infection can be very severe and prolonged at any age. A few studies pose the hypothesis that the occurrence of a severe RSV infection in infants might be an important risk factor for the subsequent development of allergy or asthma (1).

To diagnose an RSV infection, a nasal or throat swab is tested for antigen; the detection of anti-RSV IgA with seroconversion of anti-RSV IgG is evidence of recent infection; the IgG antibodies, in particular, can persist longer; reinfections can but do not have to be associated with the finding of anti-RSV IgA (3).

In the differential diagnosis of acute lower respiratory tract infections, parainfluenza viruses, adenoviruses, influenza viruses, rhinoviruses, enteroviruses are possible or Chlamydia trachomatis respectively Pneumocystis carinii, when there are signs of immunosuppression (4).

3. Test Principle

The antibody searched for in the human serum forms an immune complex with the antigen coated on the microtiter-plate. Unbound immunoglobulins are removed by washing processes. The enzyme conjugate attaches to this complex. Unbound conjugate is again removed by washing processes. After adding the substrate solution (TMB), a blue dye is produced by the bound enzyme (peroxidase). The color changes to yellow when the stopping solution is added.

4. Package Contents

4.1 IgG/IgM Testkit

1. **1 Microtiter-Plate** consisting of 96 with antigen coated, breakable single wells, lyophilised
2. **PBS-Dilution Buffer (blue, ready to use) 2x50ml**, pH 7,2, with preservative and Tween 20
3. **PBS-Washing Solution (20x concentrated) 50ml**, pH 7,2, with preservative and Tween 20
4. **IgG negative Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
5. **IgG cut-off Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
6. **IgG positive Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
7. **IgM negative Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
8. **IgM cut-off Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
9. **IgM positive Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
10. **IgG-Conjugate (anti-human), 11ml**, (sheep or goat)-horseradish-peroxidase-conjugate with protein-stabilizer and preservative in Tris-Buffer, ready to use
11. **IgM-Conjugate (anti-human), 11ml**, (sheep or goat)-horseradish-peroxidase-conjugate with FCS and preservative in Tris-Buffer, ready to use

12. **Tetramethylbenzidine substrate solution (3,3',5,5'-TMB), 11ml**, ready to use
13. **Citrate-Stopping Solution, 6ml**, contains an acid mixture

4.2 IgA Set

1. **IgA negative Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
2. **IgA cut-off Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
3. **IgA positive Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
4. **IgA-Conjugate (anti-human), 11ml**, (sheep or goat)-horseradish-peroxidase-conjugate with FCS and preservative in Tris-Buffer, ready to use

5. Storage and Shelflife of the Testkit and the ready to use reagents

Store the testkit at 2-8°C. The shelf life of all components is shown on each respective label; for the kit shelf life please see Quality Control Certificate.

1. Microtiter strips/single wells are to be resealed in package after taking out single wells and stored with desiccant at 2-8°C. Reagents should immediately be returned to storage at 2-8°C after usage.
2. The ready to use conjugate and the TMB-substrate solution are sensitive to light and have to be stored in dark. Should there be a color reaction of the substrate dilution due to incidence of light, it is not useable anymore.
3. Take out only the amount of ready to use conjugate or TMB needed for the test insertion. Additional conjugate or TMB taken out may not be returned but must be dismissed.

Material	Status	Storage	Shelflife
Test Samples	Diluted	+2 to +8°C	max. 6h
	Undiluted	+2 to +8°C	1 week
Controls	After Opening	+2 to +8°C	3 months
Microtitreplate	After Opening	+2 to +8° (storage in the provided bag with desiccant bag)	3 months
Rheumatoid factor - Absorbent	Undiluted, After Opening	+2 to +8°C	3 months
	Diluted	+2 to +8°C	1 week
Conjugate	After Opening	+2 to +8°C (protect from light)	3 months
Tetramethylbenzidine	After Opening	+2 to +8°C (protect from light)	3 months
Stop Solution	After Opening	+2 to +8°C	3 months
Washing Solution	After Opening	+2 to +8°C	3 months
	Final Dilution (ready-to-use)	+2 to +25°C	4 weeks

6. Precautions and Warnings

1. Only sera which have been tested and found to be negative for HIV-1 antibodies, HIV-2 antibodies, HCV antibodies and Hepatitis-B surface-antigen are used as control sera. Nevertheless, samples, diluted samples, controls, conjugates and microtiter strips should be treated as potentially infectious material. Please handle products in accordance with laboratory directions.
2. Those components that contain preservatives, the Citrate Stopping Solution and the TMB have an irritating effect to skin, eyes and mucous. If body parts are contacted, immediately wash them under flowing water and possibly consult a doctor.
3. The disposal of the used materials has to be done according to the country-specific guidelines.

7. Material required but not supplied

1. Aqua dest./demin.
2. Eight-channel pipette 50µl, 100µl
3. Micropipettes: 10µl, 100µl, 1000µl
4. Test tubes
5. Paper towels or absorbent paper
6. Cover for ELISA-plates
7. Disposal box for infectious material
8. ELISA handwasher or automated EIA plate washing device

9. ELISA plate spectrophotometer, wavelength = 450nm, reference length = 620nm (Reference Wavelength 620-690nm)
10. Incubator

8. Test Procedure

Working exactly referring to the VIROTECH Diagnostics user manual is the prerequisite for obtaining correct results.

8.1 Examination Material

Either serum or plasma can be used as test material, even if only serum is mentioned in the instructions. Any type of anticoagulant can be used for plasma.

Always prepare patient-dilution freshly.

For a longer storage the sera must be frozen. Repeated defrosting should be avoided.

1. Only fresh non-inactivated sera should be used.
2. Hyperlipaemic, haemolytic, microbially contaminated and turbid sera should not to be used (false positive/negative results).

8.2 Preparation of Reagents

The VIROTECH Diagnostics System Diagnostica offers a high degree of flexibility regarding the possibility to use the dilution buffer, washing solution, TMB, citrate stopping solution as well as the conjugate for all parameters and for all different lots. The ready to use controls (positive control, negative control, cut-off control) are **parameter specific** and **only to use** with the plate lot indicated in the Quality Control Certificate.

1. Set incubator to 37°C and check proper temperature setting before start of incubation.
2. Bring all reagents to room temperature before opening package of microtiter strips.
3. Shake all liquid components well before use.
4. Make up the washing solution concentrate to 1 L with distilled or demineralised water. If crystals have formed in the concentrate, please bring the concentrate to room temperature before use and shake well before use.
5. High IgG-titer or rheumatoid factors may disturb the specific detection of IgM-antibodies and may lead to false positive resp. false negative results. **For a correct IgM-determination it is therefore necessary to pre-treat the sera with RF-SorboTech** (VIROTECH adsorbent). For IgM-controls a pre-absorbent treatment is not necessary.

8.3 VIROTECH ELISA Test Procedure

1. For each test run, pipette 100µl each of ready to use dilution buffer (blank), IgG- IgM- and IgA-positive, negative and cut-off controls as well as diluted patient sera. We propose a double insertion (blank, controls and patient sera); for cut-off control a double insertion is absolutely necessary. Working dilution of patient sera: 1+100; e.g. 10µl serum + 1ml dilution buffer.
2. After pipetting start incubation for 30 min. at 37°C (with cover).
3. End incubation period by washing microtiter strips 4 times with 350 – 400µl washing solution per well. Do not leave any washing solution in the wells. Remove residues on a cellulose pad.
4. Pipette 100µl of ready to use conjugate into each well.
5. Incubation of conjugates: 30 min. at 37°C (with cover).
6. Stop conjugate incubation by washing 4 times (pls. refer to point 3 above).
7. Pipette 100µl of ready to use TMB into each well.
8. Incubation of substrate solution: 30 min. at 37°C (with cover, keep in dark).
9. Stopping of substrate reaction: pipette 50µl of citrate stopping solution into each well. Shake plate carefully and thoroughly until liquid is completely mixed and a homogeneous yellow color is visible.
10. Measure extinction (OD) at 450/620nm (Reference Wavelength 620-690nm). Set your photometer in such a way that the blank value is deducted from all other extinctions. Extinctions should be measured within 1 hour after adding the stopping solution!

Pls. refer to last page for Test Procedure Scheme

8.4 Usage of ELISA processors

All VIROTECH Diagnostics ELISAs can be used on ELISA processors. The user is bound to proceed a validation of the devices (processors) on a regular basis.

VIROTECH Diagnostics recommends the following procedure:

1. VIROTECH Diagnostics recommends to proceed the validation of device referring to the instructions of the device manufacturer during the implementation of the ELISA processor respectively after bigger reparations.
2. It is recommended to check the ELISA-processor with the Validationkit (EC250.00) afterwards. A regular check using the Validationkit shall be proceeded minimum once a quarter to test the accuracy of the processor.
3. The release criteria of the Quality Control Certificate of the product must be fulfilled for each testrun.

With this procedure, your ELISA processor will function properly and this will support quality assurance in your laboratory.

9. Test Evaluation

The ready to use controls serve for a semiquantitative determination of specific IgG-, IgA- and IgM-antibodies. Their concentration can be expressed in VIROTECH units = VE. Fluctuations resulting from the test procedure can be balanced with this calculation method and a high reproducibility is achieved in this way. Use the means of the OD values for calculation of the VE.

9.1 Test function control

a) OD-values

The OD of the blank should be < 0.15.

The OD-values of the negative controls should be lower than the OD-values mentioned in the Quality Control Certificate. The OD-values of the positive controls as well as of the cut-off controls should be above the OD-values mentioned in the Quality Control Certificate.

b) VIROTECH Units (VE)

The VIROTECH Units (VE) of the cut-off controls are defined as 10 VE. The calculated VE of the positive controls should be within the ranges mentioned in the Quality Control Certificate.

If those requirements (OD-values, VE) are not fulfilled, the test has to be repeated.

9.2 Calculation of the VIROTECH Units (VE)

The extinction of the blank value (450/620nm) has to be subtracted from all other extinctions.

$$\begin{aligned} \text{VE (positive control)} &= \frac{\text{OD (positive control)}}{\text{OD (cut-off control)}} \times 10 \\ \text{VE (patient serum)} &= \frac{\text{OD (patient serum)}}{\text{OD (cut-off control)}} \times 10 \end{aligned}$$

9.3 Interpretation Scheme IgG, IgM and IgA

Result (VE)	Evaluation
< 9,0	negative
9,0 - 11,0	borderline
> 11,0	positive

1. If the measured values are above the defined borderline range, they are considered to be positive.
2. If the measured VE is within the borderline range, no significant high antibody concentration is present, the samples are considered to be borderline. For the secure detection of an infection it is necessary to determine the antibody concentration of two serum samples. One sample shall be taken directly at the beginning of the infection and a second sample 5 – 10 days later (convalescent serum). The antibody concentration of both samples has to be tested in parallel, that means in one test run. A correct diagnosis based on the evaluation of a single serum sample is not possible.
3. If the measured values are below the defined borderline range, no measurable antigen specific antibodies are present in the samples. The samples are considered to be negative.
4. A positive IgG result indicates either a past infection or a recent infection.

A positive IgM result indicates an acute infection and a positive IgA result indicates a relatively acute reinfection, as IgA can persist for a long time (6).

9.4 Limits of the Test

1. The interpretation of serological results shall always include the clinical picture, epidemiological data and all further available laboratory results.
2. Anti-doublestrand DNA (α -dsDNA) sera (ANA, systemic lupus erithematodes) show cross reactivities to the VIROTECH Diagnostics RSV ELISA.
3. Please note:

In exceptional cases it might come to false positive results due to crossreactions with other pathogens, for example with the human metapneumovirus, or due to unusually high concentrations of sera parts.

False negative results may occur in non-responders, in immunosuppressed patients or if the sample is taken too early.

10. Performance Data

10.1 Sensitivity and Specificity

To determine sensitivity and specificity sera were tested in the VIROTECH ELISA and in an ELISA of a competitor.

- 297 sera were tested in IgG, whereof 71 were concurrent negative. The calculated sensitivity and specificity is >95%.
- 253 sera were tested in IgM. The calculated specificity is >99.9%. Owing to a lack of positive sera, the analytical sensitivity could not be calculated.
- 317 sera were tested in IgA, whereof 42 were concurrent positive. The calculated sensitivity and specificity is >95%.

10.2 Prevalence (Expected Values)

The following table shows the results of the examination of blood bank sera for IgG (n=120), IgM (n=78) and IgA (n=80):

	IgG	IgM	IgA
Negative	0	78	72
Borderline	0	0	3
Positive	120	0	5

10.3 Intra-assay-Coefficient of Variation (Repeatability)

In one assay, strips of different plates of one batch were tested in a chessboard pattern with two sera. The coefficients of variation are as followed: < 9% for IgG, IgM and IgA.

10.4 Inter-assay-Coefficient of Variation (Reproducibility)

RSV ELISA IgG

Two sera were tested in 12 independent test runs by different persons in different laboratories. The obtained coefficient of variation is < 15%.

RSV ELISA IgM

Three sera were tested in 18 independent test runs by different persons in different laboratories. The obtained coefficient of variation is < 15%

11. Literature

1. Münchner RSV-Studie 1999-2001, http://www.haunerjournal-lmu.de/hj2_02/Seiten/epide.htm
2. http://www.ahc-net.at/0001/antibiotika_monitor/5_99/5_99_2.htm Neue Aspekte der Pneumonien M. Götz Abteilung für Kinder- und Jugendheilkunde mit Infektionskrankheiten, Wilhelminenspital der Stadt Wien , 5/99, S. 7
3. http://virologie.medizin.uni-essen.de/html/analysen/ana_rs.htm erstellt von Melanie Fiedler, letzte Änderung: 04.12.2002
4. Brandis, Köhler, Eggers, Pulverer, Lehrbuch der Medizinischen Mikrobiologie, 7. Auflage, Fischer 1994, S.839
5. Mikrobiologische Diagnostik und Krankenhaushygiene, MVP, 2. Ausgabe, Stand Jan 2003, S. 64
6. Friedman MG, The use of serum IgA as a diagnostic marker in viral infections, Immunology and Infectious Diseases 1, 1991, S. 228

Preparation of Patient Samples and Washing Solution

▼ **Washing Solution:** Fill up concentrate to 1 liter with aqua dest./demin.

▼ **IgG-/IgA-Samples – Dilution**
1:101

e.g.:
10 µl serum/plasma + 1000 µl Dilution Buffer
(Serum Dilution Buffer is ready to use)

▼ **IgM-Samples - Dilution**
1:101

Rheumafactor-absorption with RF-SorboTech

e.g.:
5 µl serum/plasma + 450 µl Dilution Buffer +
1 drop RF-SorboTech, incubate for 15 min. at room temperature.

Testprocedure

Samples Incubation **30 minutes at 37°C**



Wash 4times



Conjugate Incubation **30 minutes at 37°C**



Wash 4times



Substrate Incubation **30 minutes at 37°C**



Stopping



**Measure
Extinctions**

100 µl Patient Samples

blank value (Dilution Buffer) and controls

400 µl Washing Solution

Remove Residues on a Cellulose Pad

100 µl Conjugate

IgG, IgM, IgA

400 µl Washing Solution

Remove Residues on a Cellulose Pad

100 µl Substrate

50 µl Stopping Solution

shake carefully

Photometer at 450/620nm
(Reference Wavelength 620-690nm)